Description: Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries.
Home Page: www.grifols.com
Avinguda de la Generalitat, 152
Barcelona,
08174
Spain
Phone:
34 93 571 02 21
Officers
| Name | Title |
|---|---|
| Mr. Steven Francis Mayer J.D. | Exec. Chairman |
| Mr. Raimon Grifols Roura | Co-CEO & Exec. Director |
| Mr. Víctor Grifols Deu | Co-CEO & Exec. Director |
| Mr. Alfredo Arroyo Guerra | CFO & VP |
| Mrs. Eva Bastida Tubau | Corp. VP and Director of Scientific & Medical Affairs |
| Ms. Nuria Pascual Lapeña | VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer |
| Mr. David Ian Bell | Gen. Counsel & Chief Corp. Devel. Officer |
| Mr. Mateo Florencio Borrás Humbert | Corp. VP & Chief HR Officer |
| Ms. Maria Teresa-Rioné Llano | Chief Communications Officer |
| Ms. Montserrat Gaja Llamas | Chief HR Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 17.0648 |
|---|---|
| Trailing PE: | 130 |
| Price-to-Book MRQ: | 1.0261 |
| Price-to-Sales TTM: | 1.4735 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 27584 |